ArticleFrontiers in cardiovascular medicine2025
The analysis reveals novel hub genes and pathways associated with Tetralogy of Fallot.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tetralogy of Fallot (TOF) is one of the most common complex congenital heart diseases, posing a severe threat to infant health. This study aims to investigate the core genes and pathways associated with TOF to identify potential targets for prevention and intervention. This study aims to explore the core genes and pathways associated with TOF, providing a reference for identifying potential targets for the prevention and intervention of this disease. Methods: Bulk and single-cell RNA-seq datasets were employed in this study. Differentially expressed genes (DEGs) were calculated, and functional enrichment analysis was performed. The expression of the hub genes was validated by quantitative real-time polymerase chain reaction (qRT-PCR). The dysregulated genes and pathways were further validated at the single-cell resolution. Results: The DEGs analyzed from two datasets, GSE146220 and GSE217772, were subjected to intersection analysis, resulting in 29 consistently upregulated genes (UpGs) and 22 consistently downregulated genes (DpGs). The qRT-PCR analysis confirmed that the expression of upregulated and downregulated genes was generally consistent with the results of the bioinformatics analysis. Functional enrichment analysis based on four distinct databases has shown that fatty-acid beta-oxidation and related pathways were consistently enriched. With snRNA-seq data, we found that the UpGs were enriched in cardiomyocytes, and the DpGs were enriched in cardiofibroblasts. Meanwhile, it was shown that the TOF tissue had a higher ssGSEA score for fatty acid metabolism-associated pathways. Notably, these fatty acid metabolism pathways were mostly enriched in cardiomyocytes. Conclusion: This study identified that TOF DEGs are highly enriched in fatty-acid beta-oxidation and related pathways. The snRNA-seq data of TOF showed that fatty acid metabolism pathways are predominantly enriched in cardiomyocytes. These findings contribute to further understanding the potential pathogenic mechanisms of TOF and identifying potential therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.